Catch­ing up with Mer­ck in ad­ju­vant melanoma, Bris­tol My­ers bur­nish­es Op­di­vo pro­file in ear­li­er stages of can­cer

Melanoma was the first can­cer type for which Bris­tol My­ers Squibb’s Op­di­vo scored an FDA ap­proval. And the phar­ma gi­ant is still try­ing to reach more pa­tients with it.

In an­oth­er step to­ward the broad­er goal of mov­ing the PD-1 drug up the treat­ment lines, Bris­tol My­ers an­nounced that a tri­al test­ing Op­di­vo as an ad­ju­vant treat­ment for pa­tients with com­plete­ly re­sect­ed stage IIB/C melanoma met the pri­ma­ry end­point of re­cur­rence-free sur­vival.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER